Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-147430 · Präparat HOS-099656
Elderly Among 81 patients treated in the L-MIND study, 56 (69%) patients were > 65 years of age. Patients > 65 years of age had a numerically higher incidence of serious treatment emergent adverse events (TEAEs) (55%) than patients ≤ 65 years (44%). Among the 274 patients with FL treated with tafasitamab in study inMIND, 50% were ≥ 65 years of age and 20% were ≥ 75 years of age. No clinically meaningful differences in safety or effectiveness were observed between these patients and younger patients but greater sensitivity of some older individuals cannot be ruled out.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage e932c1ccf4703408af109b1d765e04a62a27de222fe9e007d7db3ab8d1d80bf0 · Zeichen 21903–22477 im Abschnitt